Practice guidelines for outpatient parenteral antimicrobial therapy (OPAT) in Germany
DGI · 2025 · Germany
Source and licence
- Authors
- Lukas Tometten, Ulrike Trost, Linda Jürgens et al.
- Title
- Practice guidelines for outpatient parenteral antimicrobial therapy (OPAT) in Germany
- Journal
- Infection, 2025
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC12675535
Licence statement of the original publication
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.
Abstract
Purpose: The practice guideline for outpatient parenteral antimicrobial therapy (OPAT) aims to encourage broader adoption of OPAT into routine clinical practice in Germany.
Methods: The guideline was developed according to the guideline development framework by the Association of the Scientific Medical Societies (AWMF) in Germany. Literature search was conducted, and expert recommendations were formulated through consensus and published as an AWMF S1 guideline (expert group recommendations with consensus development in an informal process).
Results: OPAT is a safe and effective alternative to inpatient care for managing selected infectious diseases (ID) entities, which require intravenous antimicrobial therapy (AMT). ID specialists play a critical role in determining the indications for OPAT, the selection of suitable patients and the development of treatment plans. Specialist-led OPAT programs have been shown to enhance treatment efficacy, reduce hospital readmissions, and decrease healthcare costs. A structured, checklist-based approach is used to evaluate infection severity, available therapeutic options, patient comorbidities, and home care conditions. Adherence to antimicrobial stewardship (AMS) principles as well as regular clinical and laboratory monitoring are essential to ensure appropriate antimicrobial use and minimize adverse events, catheter-related complications and the risk of resistance. The selection of adequate vascular access is based on patient-specific factors, characteristics of the indicated antimicrobial and treatment duration, optimizing both safety and patient comfort.
Conclusion: OPAT is a safe, cost-effective alternative to inpatient care, requiring specialists’ ID expertise and AMS. The guideline provides a framework for successful implementation in Germany.
Contents of the original publication
The section headings of the original.
- Background
- Methods
- Key recommendations
- ID specialist In OPAT management
- Selection of OPAT patients
- Antimicrobial stewardship (AMS)
- Selection of antimicrobial agent
- Selection of intravenous access
- Monitoring
- Conclusion and outlook
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint